• Empowering Wellness...

Survanta 8ml Injection in Rwanda

Survanta 8ml Injection

SKU: SURVANTA-8ML-INJECTION
$198.00$180.00
CategoriesCritical Care
Manufacturer/Marketed ByABBOTT
Inquiry on WhatsApp

Active Pharmaceutical Ingredient

<p>Beractant</p>

Product Information

Survanta 8ml Injection is a pharmaceutical product available for international pharmaceutical supply. Siddha Global is an India-based pharmaceutical exporter serving international buyers, importers, distributors and healthcare organizations.

We accept enquiries for Survanta 8ml Injection for Rwanda, subject to product availability and applicable regulatory and import requirements.

For pricing, availability and bulk supply, contact Siddha Global with your required quantity and procurement details.

Survanta 8ml Injection Supplier for Rwanda

Siddha Global supplies pharmaceutical products to international markets and accepts enquiries from qualified pharmaceutical buyers in Rwanda.

We work with:

  • Pharmaceutical importers
  • Pharmaceutical distributors
  • Pharmaceutical wholesalers
  • Hospitals and healthcare organizations
  • Pharmaceutical companies
  • Authorized procurement organizations

Buyers can contact us for Survanta 8ml Injection availability, pricing and bulk supply requirements.

Buy Survanta 8ml Injection for Rwanda

If you are looking to source Survanta 8ml Injection in Rwanda, send us your requirements.

Please provide:

  • Required quantity
  • Product name and presentation
  • Destination country: Rwanda
  • Packaging requirements
  • Delivery requirements

Our team will review your enquiry and provide relevant product and commercial information.

Why Choose Siddha Global?

Pharmaceutical Exporter from India

Siddha Global is an India-based pharmaceutical exporter supplying pharmaceutical products to international markets.

International Pharmaceutical Supply

We support pharmaceutical sourcing requirements for importers, distributors and other qualified international buyers.

Bulk Pharmaceutical Orders

We accept enquiries for bulk pharmaceutical requirements based on product availability and applicable market requirements.

Export Support

We assist international buyers with relevant commercial and export requirements for pharmaceutical orders.

Frequently Asked Questions

What is Survanta 8ml Injection?

Survanta 8ml Injection is a pharmaceutical injectable product available in an 8ml presentation for international pharmaceutical sourcing.

Is Survanta 8ml Injection available in Rwanda?

Siddha Global accepts enquiries for Survanta 8ml Injection supply to Rwanda, subject to product availability and applicable Rwandan regulatory and import requirements.

What is the presentation of Survanta Injection?

Survanta is available in an 8ml presentation as specified for this product.

Can I order Survanta 8ml Injection in bulk?

Yes. Qualified pharmaceutical importers, distributors and other authorized buyers can submit bulk requirements to Siddha Global for availability and commercial information.

How can I request a quotation for Survanta 8ml Injection?

Send us your required quantity, destination country and packaging requirements. Our team can review your enquiry and provide relevant quotation information.

Who can enquire about Survanta 8ml Injection?

Pharmaceutical importers, distributors, wholesalers, healthcare organizations and other appropriately authorized organizations can contact Siddha Global regarding pharmaceutical procurement.

Request a Quote for Survanta 8ml Injection

Looking for Survanta 8ml Injection in Rwanda?

Contact Siddha Global for product availability, pricing and bulk pharmaceutical supply enquiries.

Prevention and treatment of Respiratory Distress Syndrome (RDS) in premature infants with a birth weight of 700 g or more. Helps reduce surface tension in the lungs, allowing easier breathing and improved oxygen exchange. Supports lung function in preterm newborns, especially those born before 32 weeks of gestation. Used in neonatal intensive care units (NICUs) as part of respiratory support for infants requiring endotracheal intubation and mechanical ventilation. Plays a crucial role in stabilizing critically ill premature babies at high risk of developing RDS. Aids in reducing the need for prolonged respiratory support and improving overall survival rates in neonates.

Restores normal lung function: Replaces the missing or inactive surfactant in premature infants’ lungs, enabling proper breathing. Prevents and treats Respiratory Distress Syndrome (RDS): Reduces the severity and complications of RDS in preterm newborns. Improves oxygenation and ventilation: Enhances gas exchange and lung compliance, supporting effective respiration. Reduces the need for mechanical ventilation: Helps stabilize infants faster, potentially shortening NICU stay and ventilation time. Clinically proven and safe: Manufactured under stringent quality standards and widely used in neonatal care worldwide. Supports early survival and recovery: Improves the overall outcome of premature infants, promoting healthier development during the critical early stage.

As with all medicines, Servant Injection 150 mg may cause side effects which do not require medical attention and which will disappear as your body adjusts to the medicine. If they persist or you're concerned about them, tell your doctor.

Noisy or irregular breathing after administration Mild bleeding or discharge around the endotracheal tube Feeding difficulties or reflux Temporary slowing of heart rate (bradycardia) Oxygen desaturation (brief drop in oxygen levels)

Survanta is administered only by trained healthcare professionals in a hospital or neonatal intensive care setting. The medication is given directly into the lungs through an endotracheal tube after the infant has been intubated and stabilized. The dose and timing depend on the newborn’s weight, gestational age, and respiratory condition. It may be used as a preventive dose shortly after birth in high-risk preterm infants, or as a rescue treatment for those already showing signs of Respiratory Distress Syndrome (RDS). During and after administration, the infant’s breathing, heart rate, and oxygen levels are closely monitored by the medical team. Repeated doses may be given if symptoms persist, always under strict neonatal supervision.

Survanta should be administered only under the supervision of a qualified neonatologist or healthcare professional experienced in managing premature infants with Respiratory Distress Syndrome (RDS). It must be used strictly within a hospital or neonatal intensive care unit (NICU) equipped for endotracheal intubation and continuous monitoring. Careful observation of the infant’s heart rate, oxygen saturation, and lung function is essential during and after administration. The product should not be shaken or diluted, and any unused portion should be discarded immediately after use. Parents and caregivers should be informed that Survanta is not for home use and should never be self-administered. Report any signs of allergic reaction, persistent breathing difficulty, or unusual skin discoloration to the attending physician promptly. Proper handling, storage (as per label instructions), and disposal protocols must be followed to maintain product safety and sterility.
Chat with Siddha Global on WhatsApp